Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 to 75

Norepinephrine irrigation to help stop bleeding during flexible ureteroscopic lithotripsy

Official title: Hemostasis and Safety Analysis of Norepinephrine Irrigation Fluid in Su-FURS Combined With NPUAS Lithotripsy. (Su-FURS: Single-use Flexible Ureteroscope, NPUAS: Negative Pressure Ureteral Access Sheath)

Run by Geriatric Hospital of Nanjing Medical University · NCT07786844 · Data updated 2026-11-12

This study tests whether a norepinephrine-powered irrigation solution can help control bleeding during flexible ureteroscopic lithotripsy for upper urinary tract stones in adults.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment55 (estimated)
SponsorGeriatric Hospital of Nanjing Medical University
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedApril 21, 2025
Main results expectedDecember 30, 2026
Study endsDecember 30, 2026
Registry record updatedAugust 26, 2026
Trial IDNCT07786844 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-75 with renal or upper-ureteral stones requiring supraflexible ureteroscopic lithotripsy with negative pressure ultrasound lithotripsy.

Probably not a fit

Patients with non-upper urinary tract stones, intolerance to the procedure, uncontrolled hypertension, or coronary artery disease may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-arm interventional study investigates the safety and effectiveness of a low-concentration norepinephrine irrigation solution used during lithotripsy with a flexible ureteroscope and negative pressure ultrasound sheath. Patients with kidney or upper-urinary tract stones requiring surgery will receive the norepinephrine-containing irrigation to aid hemostasis while the procedure is performed. Outcomes will focus on bleeding control, visualization, stone clearance, and adverse events to determine if this approach is feasible in clinical practice. The trial is conducted at a single center and targets adults up to age 75.

Why it matters

Potential benefit: If successful, the approach could improve intraoperative bleeding control and visualization, potentially enhancing stone clearance and safety.

How similar studies have gone: Previous studies suggest that vasoconstrictive agents can aid hemostasis in endourological procedures, but this specific norepinephrine irrigation approach is novel in this setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

* Age 18-75 years of either sex.
* Clinically and radiologically confirmed renal or upper-ureteral stone with operative indication for super flexible ureteroscopic lithotripsy combined with negative pressure ultrasound lithotripsy (su-fURS + NPUAS).
* Subjects with definite surgical indication for upper urinary tract stones, tolerate general anesthesia, and agree to receive the targeted operative procedure.

Exclusion Criteria

* Diagnosis of non-upper urinary tract stones.
* Intolerance to flexible ureteroscopic surgery.
* Poorly-controlled hypertension with blood pressure greater than 160/100 mmHg.
* History of coronary artery disease.

Where it's running

  • Geriatric Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.